AUTHORS
Nicholas Short, MD, Irina Amitai, MD2, Boaz Nachmias, MD PhD3, Avraham Frisch, MD4, Nick de Jonge, MD5, Carmen Martínez Chamorro6, Mónica Cabrero, MD7, Gunhild Mandrup Thomsen8, Tomomi Tobai9, Yakir Moshe, MD, PhD10, Ulrik Overgaard11, Cristina Papayannidis, MD, PhD12, Nicolas Boissel, MD,PhD13, Claire Heffernan14, Razia B. Akhtar, MD15, Mohammed Z.H. Farooqui, DO16, Ryan D Cassaday17
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
3 Leukemia Service, Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
4 Rambam Health Care Campus, Haifa, Israel
5 Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
6 Hospital Universitario Quirónsalud Pozuelo, Madrid, Spain, Universidad Europea de Madrid, Madrid, Spain
7 Hospital Universitario de Salamanca, Salamanca, Spain
8 Odense University Hospital, Odense, Denmark
9 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
10 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
11 National Hospital Copenhagen, Copenhagen, Denmark
12 IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia “Seragnoli”, Bologna, Italy
13 Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France
14 Merck & Co., Inc., Rahway, New Jersey, United States
15 Merck & Co., Inc., Rahway, New Jersey, United States
16 Merck & Co., Inc., Rahway, New Jersey, United States
17 University of Washington School of Medicine & Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
Background: Immunotherapeutic agents are widely used to treat B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains common. MK-1045, a humanized bispecific IgG4 CD19 × CD3 T-cell engager with an extended half-life, has shown promising safety and preliminary antileukemic activity in patients with relapsed or refractory (R/R) B-ALL (Wang Y et al. Blood. 2025;146:647-648). Here, we describe the design of the randomized, active-controlled, open-label, international phase 2/3 WaveSpan-005 study (NCT07570173), which will evaluate the efficacy and safety of MK-1045 versus blinatumomab in patients with R/R CD19-positive B-ALL.
Study Design and Methods: Eligible participants are aged ≥12 years with a confirmed diagnosis of R/R B-ALL and ≥5% bone marrow blasts. Additional inclusion criteria include CD19-positive disease confirmed by flow cytometry and/or immunohistochemistry, Philadelphia chromosome-negative disease confirmed by BCR::ABL1 testing, a Lansky Play-Performance Scale score of ≥50 for participants aged <16 years, and an Eastern Cooperative Oncology Group Performance Status score of 0-2 for those aged ≥16 years.
Key exclusion criteria include Burkitt leukemia according to the World Health Organization classification, clinically significant central nervous system diseases, and clinically significant cardiovascular or cerebrovascular diseases. Prior anti-CD19 therapy is permitted.
The study consists of 2 parts. In Part 1 (phase 2; dose optimization), approximately 30 participants will be randomized 1:1 to receive MK-1045 intravenously (IV) at either the recommended phase 2 dose (RP2D) or the RP2D-1 dose, selected based on prior clinical data. In Part 2 (phase 3), approximately 310 participants will be randomly assigned 1:1 to receive MK-1045 (at the optimal dose from Part 1) or blinatumomab IV. Randomization will be stratified by baseline bone marrow blast percentage (<50% vs ≥50%), disease status (primary refractory, first relapse, second or later relapse, or post-allogeneic hematopoietic stem cell transplantation [allo-HSCT]), and geographic (Western Europe/US/Canada/Australia vs East Asia vs rest of world). The target dose will be administered weekly during the 28-day cycle. In Part 2, blinatumomab will be administered by continuous IV infusion at the recommended starting dose on days 1-7, followed by the full dose on days 8-28 of cycle 1.
The primary endpoints for Part 1 are (a) complete response (CR) within the first 3 cycles, as assessed by the Investigator, and (b) safety and tolerability, including incidence and adverse events (AEs) and treatment discontinuations due to AEs. The primary endpoints for Part 2 are (a) CR within the first 3 cycles, as assessed by Clinical Adjudication Committee, and (b) overall survival (OS).
Secondary endpoints include (a) OS (Part 1), (b) measurable residual disease negativity of 10-4 via next-generation sequencing within the first 3 cycles (Parts 1 and 2), (c) rates of CR, CR with partial hematologic recovery (CRh), or CR with incomplete count recovery (CRi) within the first 3 cycles (Parts 1 and 2). Additional secondary endpoints for Part 2 include (a) duration of CR/CRh, duration of CR/CRh/CRi, event-free survival, (b) rate of subsequent allo-HSCT, and (c) safety and tolerability.
Primary efficacy analyses will be performed in the intent-to-treat population in both parts. Sensitivity analyses for efficacy in Part 1 will be conducted in the all-participants-as-treated (APaT) population. Safety analyses will be performed in the APaT population. AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse events (CTCAE), version 5.0, or by the American Society for Transplant and Cellular Therapy (ASTCT) grading for the incidence of cytokine-release syndrome and ICANS. Enrollment is ongoing.
DISCLOSURES
Nicholas Short, MD: Sanofi - Honoraria; Astellas Pharma Inc - Honoraria; Pfizer Inc - Honoraria; BeiGene - Honoraria; AstraZeneca - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Takeda - Honoraria; Merck - Honoraria; Adaptive Biotechnologies - Honoraria; Xencor - Research Funding; Hemogenyx - Research Funding; Astellas Pharma Inc - Research Funding; Takeda - Research Funding; Nexcure - Research Funding; Remedy Plan - Research Funding; NextCure - Research Funding; Vironexis - Research Funding; Takeda Oncology - Research Funding; GSK - Research Funding; Stemline Therapeutics - Research Funding; Novartis - Research Funding; Ascentage - Research Funding; Honoraria - Research Funding; Pfizer Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); AB Science - Consultancy (Includes expert testimony); NKARTA - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)